PRMT5 and neoplasm: The study demonstrated anti-tumor activity in lung, pancreatic, and mesothelioma cancers, and provided partial early clinical data, highlighted by partial responses in six patients [142] A total of 39 patients with advanced MTAP-deleted solid tumors were enrolled in the phase I trial of the PRMT5 inhibitor AMG 193.